Table 3

Comparisons of renal-related indicators, therapeutic strategies and outcomes

Clinical characteristicsMean±SD/Positive (%)Nominal p value
High 2019 criteria score (n=59)Low 2019 criteria score (n=61)
Follow-up period, month34.21±17.1631.54±17.250.400
AKI31 (52.54%)19 (31.15%)0.018
SCr123.60±71.02100.51±85.680.001
Alb25.64±5.4126.60±6.830.502
eGFR79.86±35.4986.86±34.740.009
uPCR4.33±2.873.97±3.910.107
Induction treatment
 Methylprednisolone pulse23 (38.98%)15 (24.59%)0.090
 Prednisone10 (16.95%)19 (31.15%)0.267
 Prednisone+MMF17 (30.51%)19 (31.15%)
 Prednisone+CTX18 (28.81%)13 (21.31%)
 Prednisone+FK50613 (22.03%)8 (13.11%)
 Prednisone+MMF+FK5061 (1.69%)2 (3.28%)
Temporary dialysis9 (15.25%)2 (3.28%)0.028
Maintenance treatment
 Prednisone11 (18.64%)21 (34.43%)0.08
 Prednisone+MMF26 (44.07%)20 (32.79%)
 Prednisone+FK50610 (16.95%)4 (6.56%)
 Prednisone+MMF+FK5064 (6.68%)9 (14.75%)
 Others7 (11.86%)7 (11.48%)
Treatment response
 Renal CR35 (59.32%)42 (68.85%)
 Renal PR20 (33.90%)15 (24.59%)0.52
 No remission4 (6.78%)4 (6.56%)
Long-term outcome
 Flare10 (16.95%)4 (6.56%)0.093
 ERSD1 (1.69%)1 (1.64%)1.000
 Death2 (3.39%)1 (1.64%)0.616
  • P-values <0.05 were considered as significance and marked in bold.

  • AKI, acute kidney injury; Alb, albumin; CR, complete remission; CTX, cyclophosphamide; eGFR, estimated glomerular filtration rate; ERSD, end-stage renal disease; MMF, mycophenolate mofetil; PR, partial remission; SCr, serum creatinine; uPCR, urine protein creatinine ratio.